All News
Filter News
Found 2,940 articles
-
Synthego Snags $110 Million in Series C to Advance Vision of Making CRISPR Technology More Available
10/23/2018
Genome engineering company Synthego received an infusion of $110 million from a Series C financing round led by Peter Thiel’s Founders Fund. The funds will be used to accelerate the company’s vision to make CRISPR technology more accessible to researchers. -
CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA Rabies Vaccine
10/23/2018
CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the initiation of its Phase I dose-escalation clinical trial with the novel mRNA-based rabies vaccine, CV7202.
-
Synthego Receives $110M in Funding to Accelerate Global Access to Genome Engineering
10/23/2018
Series C investment expedites Synthego's CRISPR product expansion to facilitate industry development of new therapies, adds cell therapy pioneer Dr. Matthew Porteus to advisory board
-
Cybrexa Therapeutics Expands Scientific Advisory Board Ahead of IND Filing
10/22/2018
Dr. Geoffrey Shapiro and Dr. Timothy Yap bring extensive expertise in targeting cell-cycle and DNA repair mechanisms in oncology drug development
-
19 (at Least!) of TIME Magazine’s 50 Most Influential Healthcare People Have Biopharma Ties
10/19/2018
TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry. -
IDT showcases CRISPR expertise in Europe
10/19/2018
As an advocate for the genomics age, Integrated DNA Technologies (IDT), will showcase its renowned CRISPR expertise at a series of European-focused events.
-
Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer
10/18/2018
Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of João Siffert, M.D. as Head of Research and Development and Chief Medical Officer.
-
Five Distinguished Individuals to be Honored with Highest American Cancer Society Award
10/17/2018
Volunteer Leaders to Receive Medal of Honor
-
ERS Genomics and Syngulon Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Industrial Applications
10/16/2018
ERS Genomics Limited and Syngulon announced today a non-exclusive license agreement which provides Syngulon with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in combination with Syngulon Patent Rights.
-
10x Genomics Showcases New Solutions at ASHG 2018
10/16/2018
Introduces significant advances to its flagship Single Cell Gene Expression Solution
-
Applied StemCell has Joined the NIST, Genome Editing Consortium
10/15/2018
Applied StemCell, Inc. (ASC), a leading gene-editing company, announced that it has joined the National Institute of Standards and Technology (NIST) Genome Editing Consortium
-
Berkeley Lights Closes $95 Million Funding Round To Expedite Commercial Expansion And Platform Development For Cell Therapy
10/15/2018
Financing will also be used to drive R&D and further expand commercial activities for digital cell biology worldwide
-
Refuge Biotechnologies Appoints Scott Smith to Board of Directors
10/15/2018
Former President and COO of Celgene to Help Guide Pipeline and Corporate Development Activities.
-
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
-
University of Iowa and Feldan Therapeutics awarded grant by the National Institutes of Health
10/12/2018
David Guay, Research Director of Feldan Therapeutics (hereafter "Feldan") announced that his collaborator, Dr. Paul McCray from the University of Iowa Carver College of Medicine, was awarded a $2 million grant
-
In May the FDA placed a hold on the trial and IND for CTX001, an investigational gene editing treatment, citing concerns over questions that had not been addressed in the IND.
-
GenAhead Bio and ERS Genomics Enter into CRISPR/Cas9 License Agreement
10/9/2018
GenAhead Bio Incorporated and ERS Genomics Limited announced today a non-exclusive license agreement to provide GenAhead with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents.
-
Cellecta, Inc. Introduces CloneTracker XP™ Expressed Lentiviral Barcode Libraries and CloneTracker XP™ Barcoded CRISPR Libraries
10/9/2018
Label individual cells with uniquely identifiable, expressed barcodes to understand how different experimental conditions affect distinct groups of cells from a common progenitor.
-
Genetics Research LLC Granted Patent for Novel CRISPR-Associated Method for Nucleic Acid Enrichment
10/9/2018
Genetics Research LLC announced today that the U.S. Patent and Trademark Office granted the Company U.S. Patent No. 10,081,829.
-
Axcelead Drug Discovery Partners and ERS Genomics Enter into CRISPR/Cas9 License Agreement
10/4/2018
Axcelead Drug Discovery Partners, Inc. announced today a non-exclusive license agreement to provide Axcelead with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual property to enhance their drug discovery service offering. ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, co-inventor of the breakthrough gene editing technology.